Table 4. Combination of atrial fibrillation and chronic kidney disease and risk of bleeding, ischemic stroke and mortality stratified for antithrombotic therapy.

				ANTITHROMBOTIC USERS			ANTITHROMBOTIC NON-USERS
Atrial fibrillation	Chronic kidney disease		Number of events	*Adjusted HR (95%CI)		Number of events	*Adjusted HR (95%CI)
BLEEDING
No	No	N = 4,027	70	1 (ref)	N = 5,241	141	1 (ref)
Yes	No	N = 60	2	1.4 (0.4–5.9)	N = 314	16	1.9 (1.1–3.3)
No	Yes	N = 866	38	1.5 (1.0–2.4)	N = 1,561	78	1.5 (1.1–2.0)
Yes	Yes	N = 59	14	4.0 (2.1–7.8)	N = 266	23	2.6 (1.7–4.2)
ISCHEMIC STROKE
No	No	N = 4,027	64	1 (ref)	N = 5,241	169	1 (ref)
Yes	No	N = 60	3	2.8 (0.9–9.2)	N = 314	16	1.6 (0.9–2.6)
No	Yes	N = 866	24	1.1 (0.7–1.8)	N = 1,561	99	1.7 (1.3–2.2)
Yes	Yes	N = 59	10	3.8 (1.9–7.9)	N = 266	36	3.9 (2.6–5.7)
MORTALITY
No	No	N = 4,027	361	1 (ref)	N = 5,241	828	1 (ref)
Yes	No	N = 60	6	0.8 (0.4–1.8)	N = 314	69	1.5 (1.2–2.0)
No	Yes	N = 866	232	1.7 (1.4–2.0)	N = 1,561	515	1.4 (1.3–1.6)
Yes	Yes	N = 59	50	3.1 (2.2–4.2)	N = 266	142	2.1 (1.8–2.6)

Abbreviations: HR, hazard ratio; CI, confidence interval.

Notes:

*Adjusted: Hazard ratio adjusted for age, sex, body mass index, hypertension, stroke, myocardial infarction, peripheral arterial disease, heart failure, diabetes mellitus and hemoglobin levels.